GLP-1 agonist drugs are showing increasing promise in controlling atrial fibrillation (Afib) in obese patients.[1] Obesity is associated with a higher risk of onset, progression and recurrence of Afib and is the second most important risk factor after arterial hypertension.[1][9] These drugs, such as semaglutide and liraglutide, promote weight reduction by slowing gastric emptying, inducing satiety, and reducing appetite.[1] A study demonstrated a 20% reduction in adverse cardiovascular events in patients on semaglutide.[1] Weight reduction leads to reverse remodeling of heart chambers and regression of Afib from persistent to paroxysmal form until its complete disappearance.[1] GLP-1 drugs are applied subcutaneously and their effect is supported by clinical studies.[1] Observational data suggest that this approach better resolves arrhythmia in patients after catheter ablation.[original content]